Sana Biotechnology
SANA
136 hedge funds and large institutions have $493M invested in Sana Biotechnology in 2023 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 42 increasing their positions, 39 reducing their positions, and 10 closing their positions.
130% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 10
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
24% more call options, than puts
Call options by funds: $204K | Put options by funds: $165K
11% more funds holding
Funds holding: 123 → 136 (+13)
8% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 39
5.72% less ownership
Funds ownership: 70.47% → 64.75% (-5.7%)
39% less capital invested
Capital invested by funds: $804M → $493M (-$311M)
Top Buyers
Top Sellers
SANA Hedge Fund Activity: Q3 2023 in Review
136 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Sana Biotechnology (SANA) for Q3 2023, worth a combined $493M — down 39% from $804M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new SANA positions and 10 closed out — a net gain of 13 holders — while 42 added to existing stakes and 39 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $10.2M. The largest seller was Flagship Pioneering, cutting an estimated $44.5M.
- 136 institutional investors held Sana Biotechnology (SANA) as of Q3 2023, up from 123 in Q2 2023.
- Funds reported $493M of Sana Biotechnology stock for Q3 2023, down 39% quarter-over-quarter.
- 23 funds opened new Sana Biotechnology positions in Q3 2023 and 10 closed out, a net change of +13 holders.
- The largest Sana Biotechnology buyer in Q3 2023 was T. Rowe Price Associates, an estimated $10.2M added.
- The largest Sana Biotechnology seller in Q3 2023 was Flagship Pioneering, an estimated $44.5M sold.
Based on aggregated 13F filings for Q3 2023.